Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics is moving from regulatory approval toward commercialization of LYTENAVA for wet age-related macular degeneration. The company has added commercial and finance leadership, raised capital for its U.S. launch, and reported continued losses with limited cash before that financing. OTLK was down 2.05% today on a full-day basis, according to the provided market data.